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Nephrotoxicity has been recognized as a major
complication of aminoglycoside antibiotics for
many years. During the past 6 to 8 years, this prob-
lem has attracted the attention and interest of a
number of investigators, resulting in the generation
of a large body of experimental data that has greatly
expanded our understanding of the pathogenesis of
this disorder. The purpose of this paper is to review
recent advances in this field.
Animal models
Our knowledge of the pathogenesis of amino-
glycoside nephrotoxicity has been generated in
large measure by studies performed in animal mod-
els [1—9]. The major criticism leveled at such studies
is that the animal models may not accurately mimic
the disease observed in humans because the thresh-
old for aminoglycoside nephrotoxicity in most ani-
mals appears to be 13- to 60-fold greater than that
deduced for humans [10]. Nevertheless, some ani-
mal models, such as the Fischer 344 rat strain [2],
do exhibit sensitivity to the nephrotoxic effect of
aminoglycosides similar to that of humans. More-
over, the renal functional and histopathologic le-
sions demonstrated by these "sensitive" animals
are similar to those observed in animal models with
a high injury threshold. Once the injury threshold is
exceeded, all animal models, whether sensitive or
resistant, exhibit similar functional and histopatho-
logic lesions.
Functional correlates of aminoglycoside nephrotoxicity
Urine concentrating capacity. A decrease in
urine concentrating capacity is one of the earliest
abnormalities of renal function detected in animal
models of aminoglycoside nephrotoxicity [2, 4, 5].
This abnormality may explain the observation that
aminoglycoside antibiotics are a common cause of
nonoliguric acute renal failure in human subjects
[11]. The urine concentrating defect appears before
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whole kidney GFR is measurably reduced; it is not
accompanied by increased urinary solute excretion
or a fall in the tubular reabsorption of solute-free
water; and administration of exogenous vasopressin
does not correct the abnormality [4]. Cohen, Lap-
kin, and Kaloyariides [4] proposed that impaired
urine concentrating capacity was due to a decreased
number of functioning nephrons accompanied by a
compensatory increase in filtration rate and a mild
solute diuresis per residual nephron. Other investi-
gators have presented preliminary evidence in sup-
port of the hypothesis that aminoglycosides inter-
fere with the action of vasopressin on the distal
nephron [11, 12]. It should be noted, however, that
histopathologic lesions are confined to the proximal
tubule [2, 3, 7, 8].
Proteinuria. Increased urinary protein excretion
is another early manifestation of aminoglycoside
nephrotoxicity [3, 5, 14]. The proteinuria is mild
and usually appears before there is frank depression
of GFR. Evidence of proximal tubular cell injury by
light and electron microscopy [2, 3, 7, 8], together
with increased urinary excretion of B2-micro-
globulin [15], supports the conclusion that the pro-
teinuria is of tubular origin.
Enzymuria. Aminoglycoside antibiotics promote
increased urinary excretion of lysosomal enzymes
[3, 5, 16, 17], as well as membrane-bound enzymes
derived from proximal tubular cells [18, 19]. Lyso-
somal enzymuria may be derived from exocytosis
of phagolysosomes with release of lysosomal en-
zymes into the tubular lumen or from frank proxi-
mal tubular cell necrosis. The increased urinary ex-
cretion of y-glutamyl transferase [18] and alanine
aminopeptidase [19] may reflect accelerated turn-
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over of brush border membrane. Although enzy-
muria is an early sign of aminoglycoside nephrotox-
icity and typically appears before GFR becomes de-
pressed, the level of enzymuria has not been shown
to be a reliable predictor of the severity of nephro-
toxicity [20].
Alterations of proximal tubular cell transport
processes. Because aminoglycoside antibiotics
cause proximal tubular cell injury and necrosis, in-
vestigators have sought to identify alterations of
proximal tubular cell transport processes as an
early clue of aminoglycoside-induced toxicity. Co-
hen et al [4] examined the effect of gentamicin treat-
ment on para-aminohippurate (PAH) transport by
rat kidney in vivo and in vitro. Although a depres-
sion of PAH transport was anticipated, unexpect-
edly increased PAH transport in vivo and in vitro
was found within 48 hours of starting gentamicin
treatment. Moreover, stimulation of this transport
system was detected prior to alterations of other
proximal tubular cell transport processes, including
organic base and amino acid transport. In sub-
sequent studies, it was shown that stimulation of or-
ganic acid transport reflected an increased active
transport of PAH, as well as decreased passive
back-leak of PAH across the basolateral membrane
[21]. Kinetic analysis supported the conclusion that
gentamicin promoted an increase in carrier protein
postulated to mediate the transmembrane transport
of PAH [21]. In additional studies, it was shown
that other aminoglycosides share with gentamicin
the capacity to stimulate PAH transport; however,
no correlation between the capacity of aminoglyco-
sides to stimulate PAH transport and their nephro-
toxicity was discerned [22]. It should be empha-
sized that stimulation of organic acid transport was
observed early in the course of aminoglycoside ad-
ministration; with continued drug treatment, de-
pression of organic acid and organic base transport
occurred. Other investigators have reported similar
results [23].
The significance of organic acid transport stimu-
lation by aminoglycosides remains speculative. It is
noteworthy, however, that other proximal tubular
cell toxins have been reported to augment organic
acid transport early in the course of proximal tubu-
lar cell injury [24]. These observations raise the
possibility that stimulation of the organic acid trans-
port system may represent a compensatory re-
sponse to proximal tubular cell injury induced by a
variety of toxic agents.
Kiuwe and Hook [25] have examined the effect of
gentamicin on other parameters of proximal tubular
cell function. These investigators found that admin-
istration of gentamicin, 100 mg/kg/day, depressed
ammoniagenesis in renal cortical slices after 2 days
of therapy and depressed gluconeogenesis after 4
days of therapy. Glucose uptake by rat renal corti-
cal slices was not impaired, although glucosuria has
been observed in vivo [26]. The appearance of other
abnormalities of proximal tubular cell transport ap-
pears to parallel the extent of proximal tubular cell
necrosis [27].
Glomerular filtration rate. Depression of GFR is
a relatively late manifestation of aminoglycoside
nephrotoxicity. As noted above, decreased urine
concentrating capacity, proteinuria, enzymuria,
and alterations of proximal tubule organic acid
transport are characteristically seen before there is
any significant depression of GFR. In addition, his-
topathologic lesions of focal proximal tubular cell
necrosis may be present in the absence of any de-
pression of whole kidney GFR [14]. When GFR is
depressed, however, it usually parallels the severity
and extent of proximal tubular cell necrosis. Baylis,
Rennke, and Brenner [28] have shown that the de-
pression of single nephron GFR in rats injected with
gentamicin is associated with a decreased glomeru-
lar capillary ultrafiltration coefficient. These investi-
gators found no abnormalities of the glomerular
capillaries by transmission electron microscopy.
Recently, other workers, using scanning electron
microscopy, have reported a decreased number of
glomerular capillary endothelial cell fenestrations in
rats injected with gentamicin [29]. This finding may
provide an ultrastructural basis for the decline in
SNGFR associated with gentamicin nephrotoxicity.
Histopathology
Aminoglycosides induce tubular cell necrosis,
which is confined almost exclusively to the pars
convoluta and pars recta of proximal tubules [2, 3,
7, 8, 30]. The earliest identifiable lesion seen by
electron microscopy is an increase in the number
and size of secondary lysosomes, also known as
phagolysosomes or cytosegresomes, which contain
myeloid bodies (Fig. 1). The myeloid body, an elec-
tron-dense lamellar structure suggestive of con-
centrically arranged and densely packed mem-
branes, has been detected in proximal tubular cells
within 48 hours of gentamicin administration [2].
Subsequently, other changes become evident, in-
cluding a decrease in the number and height of mi-
crovillae of brush border membrane, swelling of
mitochondria, cytoplasmic vacuolization, and dila-
tation of the cisternae of rough endoplasmic reticu-
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Fig. 1. Electron micrograph of renal proximal tubule cells of a rat injected with gentamicin, 100 mg/kg for4 days. Note multiple myeloid
bodies within lysosomes, myeloid bodies in lumen, and loss of microvillae. Cellular organdies otherwise are intact. (x 17,500)
lum. These changes progress to total disorganiza-
tion and disruption of cellular organelles with frank
cellular necrosis (Fig. 2).
Determinants of aminoglycoside nephrotoxicity
Depending on the drug and dose schedule, the de-
gree of proximal tubular cell necrosis induced by an
aminoglycoside may range from a focal to a diffuse
lesion. Thus, it is possible to define a dose schedule
of an aminoglycoside that may not depress whole
kidney GFR but still causes focal tubular cell necro-
sis. For example, we have found that netilmicin and
tobramycin when administered to rats at a dose of
100 mg/kg/day for 8 days or 75 mg/kg/day for up to
28 days did not depress the creatinine clearance;
however, at every time interval of tissue sampling
we found evidence of focal tubular cell necrosis
[14]. Moreover, we also observed signs of tubular
cell regeneration in tissue sections demonstrating
tubular cell necrosis. The phenomenon of tubular
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Fig. 2. Electron micrograph of renal proximal tubule cells of a rat injected with genlamicin, 100 mg/kgfor8 days. Cell architecture on
right is totally disorganized and replaced with numerous myeloid bodies, vacuoles, and degenerating organelles. Cell architecture on left
is intact with myeloid bodies within lysosomes. Microvillae of brush border membrane can be seen. (xli ,250).
cell regeneration coexisting with tubular cell necro-
sis has been observed by other investigators [7, 8,
30]. In several studies, recovery from aminoglyco-
side nephrotoxicity was observed despite contin-
uation of aminoglycosides [31, 32]. It would appear
that early in the course of aminoglycoside adminis-
tration the most susceptible cells experience tubular
cell injury and necrosis. With continued drug ad-
ministration, another population of proximal tubu-
lar cells experience injury and necrosis. If the rate
of tubular cell regeneration keeps pace with the rate
of tubular cell necrosis, however, progressive dete-
rioration of renal function can be obviated. The de-
terminants of the apparent variable susceptibility of
proximal tubular cells to the toxic effects of amino-
glycosides have not been identified. Age, however,
may be an important factor in that young animals
appear to be less susceptible to aminoglycoside
nephrotoxicity than are older animals [1]. In addi-
tion, regenerating cells appear to be more resistant
to the toxic effects of aminoglycosides [3 1—33], al-
though the mechanism remains unknown.
The clinical threshold of aminoglycoside nephro-
toxicity, therefore, is determined by the rate of ne-
crosis and the rate of regeneration of proximal tubu-
lar cells. An increased rate of tubular cell necrosis,
possibly as a consequence of a decreased injury
threshold, or a decreased rate of regeneration could
explain a reduced clinical threshold of aminoglyco-
side toxicity. As noted above, increasing age has
been postulated to be an important risk factor for
aminoglycoside nephrotoxicity [34]. A reduced in-
jury threshold, as well as a reduced capacity for cel-
lular regeneration, could contribute to the height-
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ened risk of aminoglycoside toxicity associated
with age [9]. Studies in animals suggest frequency
of drug administration also may be a risk factor.
Plamp et a! [35] have reported that administration of
the same amount of gentamicin in three divided
doses per day was more nephrotoxic than was the
same quantity of drug injected as a single dose. The
increased nephrotoxicity was associated with in-
creased renal tissue concentration of gentamicin,
which is a major determinant of aminoglycoside
toxicity (vida infra). Duration of aminoglycoside
therapy is another obvious risk factor for nephro-
toxicity [9] and probably reflects the progressive
rise in renal cortical drug levels observed as a func-
tion of duration of therapy [36]. Nevertheless, re-
covery from aminoglycoside nephrotoxicity may
occur despite continuation of therapy. In the study
of Gilbert et al [32], recovery of renal function was
observed in the face of reaccumulation of drug in
renal cortex to levels that earlier were associated
with tubular cell necrosis. These observations im-
ply a rise in the injury threshold of regenerating epi-
thelium.
Other risk factors include reduced renal mass [9,
34], sodium depletion [37], metabolic acidosis [38],
or the concomitant administration of other nephro-
toxic agents. Prior aminoglycoside treatment has
been shown to augment the severity of proximal
tubular cell injury following exposure to another
nephrotoxin even when the dose of aminoglycoside
or nephrotoxin by itself causes only mild or no sig-
nificant injury. In rats, synergism has been demon-
strated when aminoglycosides were given in combi-
nation with mercuric chloride [33], glycerol [39], or
methoxyflurane [40]. The interaction of aminogly-
cosides with other nephrotoxic agents may underlie
the clinical expression of nephrotoxicity even when
the dose of aminoglycoside and plasma concentra-
tion of drug are well within the recommended
ranges [41, 42].
Administration of an aminoglycoside in combina-
tion with a cephalosporin has been reported to in-
crease the incidence and severity of nephrotoxicity
in human subjects [43-46]. In contrast, no syner-
gism between aminoglycosides and cephalosporins
has been demonstrated in rats [47, 48], and in sever-
al studies the concomitant administration of a ceph-
alosporin has been shown to protect against amino-
glycoside nephrotoxicity presumably by reducing
the accumulation of aminoglycoside within the re-
nal cortex [49-5 1]. The reason(s) for the discrepancy
between human studies and animal studies is not
known. It should be emphasized, however, that the
animal models do not accurately mimic the human
model in at least one important respect: the animal
models do not have an associated disease process
necessitating the administration of antibiotics. It is
conceivable that the underlying disease process in
humans may be the critically important factor nec-
essary for the interaction between aminoglycosides
and cephalosporins.
Relationship between renal accumulation of drug and
nephrotoxicity potential
It is well established that aminoglycoside antibi-
otics are concentrated within the renal cortex of
man [36, 41, 42, 52—54] and experimental animals [5,
14, 27, 32, 33, 55, 56], and it has generally been as-
sumed that the renal cortical accumulation of drug
is intimately related to the pathogenesis of amino-
glycoside nephrotoxicity. For a given amino-
glycoside, the risk of nephrotoxicity increases as
the renal cortical concentration of drug increases
[35, 36]. The concentration of drug in renal cortex
increases as a function of dose, frequency of drug
administration, and duration of drug treatment until
eventually a plateau is reached that reflects satura-
tion of the transport process or the achievement of a
balance between uptake and efflux of drug from re-
nal cortex [36]. The aminoglycosides exhibit differing
nephrotoxicity potentials, but as summarized in
Table I, the nephrotoxicity potentials of amino-
glycosides do not correlate with the degree to which
these drugs are concentrated in renal cortex. In this
study from our laboratory, rats received a daily s.c.
injection of drug for 2 to 8 days. Rats were sacri-
ficed after 2 and 4 days of injection, and the renal
cortical concentration of drug was determined by
microbiological assay [22]. The remaining rats were
sacrificed after 8 days of drug injection, and the rise
in serum creatinine was determined and used as an
indicator of nephrotoxicity. Neomycin was concen-
trated in renal cortex at a relatively low rate, yet
this drug had the highest nephrotoxicity potential of
the aminoglycosides tested. Netilmicin was accu-
mulated in renal cortex to approximately the same
extent as gentamicin, yet netilmicin's nephrotoxici-
ty potential has been shown by us [14, 22] and other
investigators [27] to be significantly less than that of
gentamicin. These observations suggest that the
nephrotoxicity of an aminoglycoside is determined
by the interaction of at least two factors. The first
determinant is the extent to which the drug is accu-
mulated within the renal cortex. Streptomycin ex-
hibits a very low rate of accumulation in renal cor-
tex, and this contributes to the low nephrotoxicity
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Table 1. Relation between renal cortical concentration of aminoglycosides and nephrotoxicity potentials"
Cortical drug concentration
pg/g wet tissue wt
Serum creatinine
mgldl
x8daysx2days X4days
Saline
Streptomycin, 100 mg/kg/day
Neomycin, 100mg/kg/day
Tobramycin, 100mg/kg/day
Kanamycin, 500 mg/kg/day
Amikacin, 500mg/kg/day
Netilmicin, 100mg/kg/day
Gentamicin, 100mg/kg/day
— —
89 8 76 10
(4) (6)
413 61 940 171
(6) (6)
519 73 833 61
(8) (7)
739 81 1156 53
(6) (6)
1067 116 1759 111
(6) (6)
1067 124 2142 222
(12) (7)
1029 114 2230 275
(8) (7)
0.34 0.02
(20)
0.33 0.02
(4)
7.19 0.58"
(6)
0.32 0.02
(8)
2.18 0.24"
(6)
0.96 0.15"
(6)
0.34 0.01
(12)
4.73 0.60"
(8)
a Data are expressed as the means SEM. Numbers in parentheses denote numbers of rats injected.
"Significantly different from control, P < 0.01.
potential of this agent. The second factor is the pro-
pensity of the drug to cause toxic injury to intra-
cellular organelles. Because netilmicin is accumu-
lated within renal cortex to approximately the same
extent as gentamicin is, it implies that netilmicin is
significantly less toxic than is gentamicin to intra-
cellular organelles. According to this scheme, neo-
mycin is more toxic than is gentamicin to intra-
cellular organelles.
Renal transport of aminoglycosides
The kidney is the major route by which amino-
glycosides are eliminated from the body. Following
a single injection, 60 to 80% of the drug is recovered
in the urine unchanged over the subsequent 24-hour
period; with repeated dosing, the daily urinary re-
covery of drug approaches 100% of the injected
dose [9]. After discontinuation of treatment, how-
ever, drug can be detected in the urine for many
days, as it is gradually released from tissue stores.
Fabre et al have estimated the half-life of gen-
tamicin in rat renal cortex to be between 98 and 166
hours [56]. Similar data have been reported in hu-
man studies [36]. The aminoglycosides have dif-
fering half-lives in renal cortex [55, 56], which may
contribute to differences in nephrotoxicity poten-
tials.
The first step in the renal elimination of amino-
glycosides involves glomerular filtration. Clearance
studies support the conclusion that the drug is ex-
creted primarily by glomerular filtration. In some
clearance studies, tubular absorption of drug has
been inferred [36, 57, 58], whereas in other studies
correction of clearance data for binding of drug to
plasma protein supports the conclusion that amino-
glycosides are also secreted [59]. Because the de-
gree of protein binding has been reported to range
from 0 to 30% [60, 61], caution should be exercised
in drawing inferences based on these protein-bind-
ing data.
We have examined the renal handling of gen-
tamicin in the Sprague-Dawley rat [62]. The steady-
state renal clearance of 14C-gentamicin was 92.5%
of the simultaneously determined inulin clearance,
a finding consistent with tubular absorption of gen-
tamicin. But correction of the clearance data for
protein binding of gentamicin, determined in vitro
by equilibrium dialysis and ultrafiltration tech-
niques, revealed no significant difference between
the steady state clearance of gentamicin and the in-
ulin clearance.
Using the microinjection technique, we were able
to demonstrate an absorptive flux of 3H-gentamicin
along the proximal convoluted tubule and loop of
Henle of superficial nephrons. We postulated that
the absorptive flux along the loop of Henle (defined
as the segment between the last accessible con-
volution of the proximal tubule and the first acces-
sible convolution of the distal tubule of superficial
nephrons) reflects transport of gentamicin along the
pars recta [62]. No absorption of gentamicin was
detected beyond the earliest accessible segment of
the distal convoluted tubule. Although the absolute
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absorptive flux of gentamicin increased as the load
of gentamicin increased, the fractional absorptive
flux decreased with increasing loads and suggested
that the mechanism mediating the absorption of
gentamicin can be saturated. No evidence of trans-
tubular secretion of gentamicin was found by the
precession technique [62].
Recently, Senekjian, Knight, and Weinman [63]
reported in abstract form their micropuncture stud-
ies of gentamicin transport in which they also found
evidence for net tubular absorption of drug along
the proximal convoluted tubule. In addition, how-
ever, these investigators obtained data consistent
with transtubular secretion of gentamicin.
The possibility of basolateral membrane trans-
port of aminoglycosides has been assessed in vitro
with the renal cortical slice technique. We [62], as
well as other investigators [64, 65], have shown that
gentamicin is accumulated in rat renal cortical slices
by a process independent of the organic acid and
organic base transport systems. That the uptake of
aminoglycosides by rat renal cortical slices is medi-
ated by a specific mechanism is suggested by the
observation that the cortical uptake of an amino-
glycoside can be competitively inhibited in vitro by
other aminoglycosides [62]. We have subsequently
found that tobramycin is accumulated to a greater
degree by rat renal cortical slices in vitro than is
gentamicin or netilmicin (unpublished observations)
whereas, in vivo, tobramycin is accumulated in the
renal cortex to a lesser extent than is gentamicin or
netilmicin [14]. If the renal cortical slice technique
indeed measures the transport of aminoglycosides
across the basolateral membrane of proximal tubu-
lar epithelium, then it follows that basolateral mem-
brane transport is quantitatively less important than
apical membrane transport in the cellular accumula-
tion of aminoglycosides. This conclusion is support-
ed by the study of Collier et al [66], who found that
the accumulation of gentamicin in the filtering iso-
lated rat kidney was four-fold greater than the accu-
mulation of gentamicin in the nonfiltering isolated
kidney, and by the study of Chiu and Long [67].
Autoradiographic tracer studies performed by
several groups of investigators support the con-
elusion that gentamicin and presumably other
aminoglycosides are transported across the apical
membrane of proximal tubular cells by pinocytosis
[68, 69]. The first step in this process is the binding
of the aminoglycoside to receptors located on the
apical membrane of proximal tubular cells. Just and
Habermann [70] have characterized the relative
binding affinities of several aminoglycosides for re-
ceptors on isolated brush border membranes and
have demonstrated competitive inhibition of recep-
tor binding of macromolecules by aminoglycosides.
The second step is the uptake of drug into apical
vesicles. Within 10 mm after a pulse injection of 3H-
gentamicin, the radioactive tracer can be demon-
strated within apical vesicles of proximal tubular
cells. One hour later the radioactive tracer can be
demonstrated within lysosomes presumably due to
the fusion of an apical vesicle with a primary lyso-
some [68, 69]. The lysosomal accumulation of
aminoglycosides has also been demonstrated by ul-
trastructural and biochemical techniques in fibro-
blasts grown in tissue culture medium containing
aminoglycosides [71, 72] and more recently in cells
of rat renal cortex [73].
Although the available evidence unequivocally
supports the intralysosomal accumulation of amino-
glycosides, it remains unclear whether pinocytosis
is the sole or even the major route by which these
drugs gain entry into proximal tubular cells. The
evidence for basolateral membrane transport of
drug has been cited above. Other investigators have
suggested that aminoglycosides may be transported
by an amino acid transport system based on the ob-
servation that infusing large doses of an amino acid
mixture decreased the renal cortical accumulation
of gentamicin in dogs [74]. In view of the large dose
of amino acids required to elicit an effect, it seems
likely that the depression of gentamicin transport
reflected the inhibitory influence of basic amino
acids on binding of gentamicin to apical membrane
receptors mediating pinocytosis rather than com-
petitive inhibition of transport by the basic amino
acid transport system itself.
Passive diffusion appears to be an unimportant
mechanism for cellular accumulation of aminogly-
cosides. Auslander, Felmeister, and Sciarrone [75]
have shown that gentamicin does not exhibit any
significant interaction with a series of biologically
important lipid membranes when examined over a
wide range of pH. This observation supports the
conclusion that gentamicin has a low lipid solubili-
ty. This conclusion is supported further by the
study of Chiu et al [76], who found that under condi-
tions of an alkaline urine, which would increase the
fraction of gentamicin existing in the unionized
form, renal cortical concentration of gentamicin de-
creased. This observation suggests that by shifting
gentamicin from the ionized to the unionized form
the extent of drug binding to apical membrane re-
ceptors was reduced, and this resulted in decreased
transport of drug into the cell.
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Fig. 3. Pathways of aminoglycoside-induced cellular injury. On the right the aminoglycoside (AG) is shown entering the cell by pino-
cytosis and subsequently fusing with a primary lysosome (L). The aminoglycoside may interfere with normal lysosomal digestion giving
rise to myeloid body formation, and the aminoglycosides may labilize lysosomes leading to the release of potent acid hydrolases into the
cytosol. If aminoglycosides gained entry into the cell by other pathways as depicted on the left, then the aminoglycosides could cause
direct injury to intracellular organelles.
Figure 3 schematically illustrates the possible
routes of entry of gentamicin into renal proximal
tubular cells. These routes include (1) apical mem-
brane transport by pinocytosis with subsequent se-
questration of drug within lysosomes, (2) apical
membrane transport by some mechanism in addi-
tion to pinocytosis, and (3) basolateral membrane
transport of aminoglycosides. It should be apparent
that the pathway(s) by which aminoglycosides gain
entry into proximal tubular cells holds important
implications for the pathogenesis of amino-
glycoside-induced nephrotoxicity as well as pos-
sible strategies for preventing aminoglycoside neph-
rotoxicity. If the aminoglycosides are transported
into proximal tubular cells primarily by pinocytosis,
then it would strengthen the hypothesis that amino-
glycoside nephrotoxicity reflects lysosomal dys-
function developing as a direct consequence of
aminoglycoside sequestration within lysosomes.
Moreover, it might be possible to devise strategies
for reducing the uptake of aminoglycosides by pino-
cytosis, either by competitive inhibition or by modi-
fication of molecular structure. Alternatively, if
aminoglycosides gain access into proximal tubular
cells by some process in addition to pinocytosis,
then the possible pathways of aminoglycoside-in-
duced injury are greatly multiplied.
Theories of pathogenesis of aminoglycoside nephrotoxicity
Lysosomal dysfunction hypothesis. The fact that
aminoglycosides induce a dramatic increase in the
number and size of secondary lysosomes containing
myeloid bodies together with the recent evidence
that aminoglycosides are accumulated within lyso-
somes immediately focuses attention on the possi-
bility that aminoglycosides may inhibit one or more
lysosomal enzymes leading to impairment of the
lysosomal digestive process and giving rise to the
myeloid body. It should be emphasized that the
myeloid body is seen in conditions other than
aminoglycoside nephrotoxicity. It has been found in
the lysosomal storage diseases that are character-
ized by genetically determined deficiency of one or
more lysosomal enzymes resulting in the accumula-
tion of incompletely degraded material within lyso-
somes [77]. Myeloid body formation can be induced
by a large number of drugs of differing chemical
structure and chemical action, but all share the
characteristic of being cationic amphiphilic com-
pounds [78-80]. These amphiphilic drugs have been
shown to be concentrated within lysosomes and to
induce a form of lipid storage disease characterized
by the formation of myeloid bodies, presumably by
inhibiting one or more lysosomal enzymes. Recent-
ly, Aubert-Tulkens, Van Hoof, and Tulkens [72] re-
ported that gentamicin accumulates within lyso-
somes and induces a phospholipidosis in fibroblasts
grown in culture medium containing gentamicin.
The phospholipidosis reflected a generalized in-
crease in all phospholipids and developed in parallel
with the formation of myeloid bodies within lyso-
somes. Lysosomal sphingomyelinase activity was
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significantly depressed, whereas the activities of 19
other lysosomal enzymes were unaltered. Morin et
a! [73] have found that treatment of Wistar rats with
gentamicin, 50 mg/kg/day for 8 days, is associated
with a depression of lysosomal sphingomyelinase
activity obtained from renal cortex. These workers
were unable to detect, however, a significant accu-
mulation of phospholipids in rat renal cortex.
We have recently examined the effect of gen-
tamicin on the phospholipid content of renal cortex
of Sprague-Dawley rats injected with gentamicin,
100 mg/kg/day for I and 2 days. The data are sum-
marized in Table 2. n contrast to Morin et al [73],
we detected a significant rise in phospholipid con-
tent of rat renal cortex after 2 days of treatment. We
have shown previously that after 2 days of treat-
ment at this dose schedule, myeloid bodies are pres-
ent; however, there is no other histologic evidence
of nephrotoxicity, and except for stimulation of or-
ganic transport, no other functional abnormalities
are detectable. Thus, a phospholipidosis of renal
cortex appears to be another early metabolic altera-
tion induced by gentamicin. We have as yet not
characterized the nature of the phospholipidosis;
nor have we determined whether the phospholipi-
dosis is associated with depression of one or more
lysosomal enzymes. Nevertheless, in view of the
studies cited above, it is reasonable to postulate
that gentamicin and presumably other aminoglyco-
sides inhibit the activity of one or more lysosomal
enzymes resulting in the accumulation of phospho-
lipids in the form of myeloid bodies, which probably
represent undegraded remnants of cytomembranes.
If it is assumed that aminoglycosides inhibit one
or more lysosomal enzymes, then the question
arises as to how inhibition of lysosomal enzymes
and the resultant phospholipidosis results in cell in-
jury and death. It is possible the impairment of the
normal lysosomal degradation process may deprive
the cell of critically important substrate. Alterna-
Table 2. Phospholipid content of rat renal cortexe
Total phospholipid
mg/g wet tissue WI
Control 27.0 0.5
(10)
Gentamicin, 100 mg/kg for I day 28.4
(10)
0.9
Gentamicin, 100 mg/kg for2days 30.5 08b
(10)
a Data are expressed as the means SEM. Numbers in paren-
theses denote numbers of rats injected.
Significantly different from control, P < 0.01.
tively, the accumulation of aminoglycosides within
lysosomes may, due to mechanical or chemical fac-
tors, promote labilization of lysosomes with the re-
lease of potent acid hydrolases intracellularly that
could attack other intracellular organelles leading to
cell injury and necrosis [81].
Other investigators have suggested that amino-
glycoside toxicity is a manifestation of altered mito-
chondrial function [6, 82]. From the available data,
it remains uncertain whether the reported changes
in mitochondrial function precede, follow, or occur
independently of impaired lysosomal function.
Summary. Aminoglycoside nephrotoxicity is
manifested functionally by decreased urine con-
centrating capacity, tubular proteinuria, lysosomal
enzymuria, mild glucosuria, decreased ammonium
excretion, and depression of GFR. Histopathologic
lesions are confined primarily to the proximal tu-
bule and consist of an increase in the number and
size of secondary lysosomes and cytosegresomes
containing myeloid bodies, disruption of brush bor-
der membranes, mitochondrial swelling, and frank
tubular cell necrosis. The first step in the pathogen-
esis of aminoglycoside toxicity involves the accu-
mulation of these drugs within renal proximal tubu-
lar epithelium. The renal handling of amino-
glycosides includes glomerular filtration and
absorption of a variable fraction of filtered drug
along the pars convoluta and pars recta mediated in
part by pinocytosis, which results in the segregation
of aminoglycoside within lysosomes. Basolateral
membrane transport of aminoglycosides has been
inferred from in vitro studies of drug accumulation
by renal cortical slices. The latter mechanism is in-
dependent of the organic acid or base transport sys-
tems. Unequivocal evidence of basolateral mem-
brane transport and transtubular secretion, how-
ever, is lacking. Transport of aminoglycosides
across the apical membrane of distal tubular epithe-
hum has not been demonstrated. All aminoglyco-
sides are concentrated in renal cortex, but there is
no correlation between cortical concentration of
drug and nephrotoxic potential. The second step in
the pathogenesis of aminoglycoside nephrotoxicity
involves the propensity of these drugs to interact
with one or more intracellular metabolic pathways.
Recent studies have shown that aminoglycosides in-
duce a phospholipidosis in cells grown in tissue cul-
ture. These findings, together with the observation
that aminoglycosides accumulate within lysosomes
and induce myeloid body formation, suggest that
aminoglycoside nephrotoxicity may be a manifesta-
tion of drug-induced lysosomal dysfunction in-
volving phospholipid metabolism.
580 Kaloyanides and Pastoriza-Munoz
Acknowledgments
This work was supported by the Medical Re-
search Service of the Veterans Administration, by
Public Health Service grant HL-19137, and by a
grant from the Schering Corporation.
Reprint requests to Dr. G. J. Kaloyanides, Division of Ne-
phrology and Hypertension, Department of Medicine, Health
Sciences Center, State University of New York at Stony Brook,
Long Island, New York 11794, USA
References
1. FLANDRE 0, DAMON M: Experimental study of nephrotoxic-
ity of gentamicin in rats, First International Symposium on
Gentamicin, Base!, Schwabe and Co., 1967, pp. 47-61
2. KOSEK JC, MAZZE RI, COUSINS MJ: Nephrotoxicity of gen-
tamicin. Lab Invest 30:48-57, 1974
3. WELWOOD JM, LOVELL D, THOMPSON AE, TIGHE JR: Re-
nal damage caused by gentamicin: A study of the effects on
renal morphology and urinary enzyme excretion. J Pathol
118: 171—182, 1976
4. COHEN L, LAPKIN R, KALOYANIDES GJ: Effect of gen-
tamicin on renal function in the rat. J Pharmacol Exp Ther
193:264—273, 1975
5. LUET FC, PATEL V, YUM MN, PATEL B, KLEJT SA: Experi-
mental aminoglycoside nephrotoxicity. J Clin Med 86:213-
220, 1975
6. VERA-ROMAN J, KRISHNAKANTHA TP, CUPPAGE FE: Gen-
tamicin nephrotoxicity in rats: I. Acute biochemical and ul-
trastructural effects. Lab Invest 33:412—417, 1975
7. CUPPAGE FE, SETTER K, SULLIVAN LP, REITZES EJ, MEL-
NYKOVycH AU: Gentamicin nephrotoxicity: II. Physiologi-
cal, biochemical and morphological effects of prolonged ad-
ministration to rats. Virchows Arch [B Cell Pathol] 34:121—
138, 1977
8. HOUGHTON DC, HARTNETT M, CAMPBELL-BOSWELL M,
PORTER G, BENNETT W: A light and electron microscopic
analysis of gentamicin nephrotoxicity in rats. Am J Pathol
82:589—612, 1976
9. APPEL GB, NEU HC: Gentamicin in 1978. Ann lntern Med
89:528-538, 1978
10. FALCO FG, SMITH HM, ARCIERI GM: Nephrotoxicity of
aminoglycosides and gentamicin. J Infect Dis 119:406-409,
1969
11. ANDERSON RJ, LINAS SL, BERNS AS, HENRICH WL, MILL-
ER TR, GABOW PA, SCHRIER RW: Nonoliguric acute renal
failure. N EngI J Med 296:1134-1138, 1977
12. BENNETT WM, PLAMP C, REGER K, MCCLUNG M, PORTER
GA: The concentrating defect in experimental gentamicin
nephrotoxicity. Clin Res 25:540A, t978
13. SOULIERE CR, GOODMAN DBP, APPEL GB, FORREST JN JR:
Gentamicin selectively inhibits antidiuretic hormone in-
duced water flow in the toad urinary bladder. Abst Am Soc
Nephrol l1:99A, 1978
14. SOBERON L, BOWMAN RL, PASTORIZA-MUNOZ E, KA-
LOYANIDES GJ: Comparative nephrotoxicities of gen-
tamicin, netilmicin and tobramycin in the rat. J Pharmacol
Exp Ther 210:334-343, 1979
15. SCHENTAG JJ, SUTFIN TA, PLANT ME, JusKo WJ: Early
detection of aminoglycoside nephrotoxicity with urinary
bete-2-microglobulin. J Med 9:201—210, 1978
16. PATEL V, LUFT FC, YUM MN, PATEL B, ZEMAN W, KLEIT
SA: Enzymuria in gentamicin-induced kidney damage. Anti-
microb Agents Chemother 7:364-369, 1975
17. WELLW000 JM, SIMPSON PM, TIGHE RR, THOMPSON AE:
Evidence of gentamicin nephrotoxicity in patients with renal
allografts. Br Med J 3:278—281, 1975
18. BECK PR, THOMPSON RB, CHAUDHURI AKR: Amino-
glycoside antibiotics and renal function: Changes in urinary
y-glutamyl transferase excretion. J Clin Pathol 30:432-437,
1977
19. MONDORF AW, HENDUS J, BEIER J, SCHERBERICH JE,
SCHOEPPE W: Tubular toxicity induced by aminoglycosides
in human kidneys, in Nephrotoxicity, edited by FILLASTRE
JP, New York, Masson Publishing USA Inc., 1978, pp. 168-
174
20. LUFT FC, PATEL V: Lysosomal acid hydrolases as urinary
markers of aminoglycoside nephrotoxicity in the rat, in
Nephrotoxiciry, edited by FILLASTRE JP, New York, Mas-
son Publishing USA Inc., 1978, pp. 127-141
21. LAPKJN R, BOWMAN R, KALOYANIDES GJ: Effects of gen-
tamicin on PAH metabolism and transport in rat kidney
slices. J Pharmacol Exp Ther 201:233-242, 1977
22. BOWMAN RL, SLLVERBLATT FJ, KALOYANIDES GJ: Com-
parison of the nephrotoxicity of netilmicin and gentamicin in
rats. Antimicrob Agents Chemother 12:474-478, 1977
23. BENNETT WM, PLAMP CE, GILBERT DN, PORTER GA: Ki-
netics of gentamicin uptake in rat cortical slices and the ef-
fect of aminoglycoside pretreatment on the transport of pars-
aminohippurate and N-methyl-nicotinamide, in Nephrotox-
icity, edited by FILLASTRE JP, New York, Masson Publish-
ing USA Inc., 1978, pp. 143—156
24. HIRSCH GH: Differential effects of nephrotoxic agents on
renal organic ion transport and metabolism. J Pharmacol
Exp Ther 186:593—599, 1973
25. KLUWE WM, HOOK JB: Functional nephrotoxicity of gen-
tamicin in the rat. Toxicol App!Pharmacol 45:163-175, 1978
26. GINSBURG DS, QUINTANILLA AP, LEVIN M: Renal glyco-
suria due to gentamicin in rabbits. J Infect Dis 134:119—122,
1976
27. LUFT FC, BLOCH R, BLOAN RS, YUM MN, COSTELLO R,
MAXWELL DR: Comparative nephrotoxicity of amino-
glycoside antibiotics in rats. J Infect Dis 138:541—545, 1978
28. BAYLIS C, RENNKE HR, BRENNER BM: Mechanism of the
defect in glomerular ultrafiltration associated with gen-
tamicin administration. Kidney Int 12:344-353, 1977
29. AVASTHI PS, HUSER J, EVAN AP: Glomerular indotheliaj
cells in gentamicin-induced acute renal failure in rats. Abst
Am Soc Nephrol 12:1A, 1979
30. HOUGHTON DC, PLAMP CE, DEFEHR JM, BENNETT WM.
PORTER G, GILBERT D: Gentamicin and tobramycin nephro-
toxicity. Am J Pathol 93:137—152, 1978
31. LUFT FC, RANKIN LI, SLOAN RS, YUM MN: Recovery
from aminoglycoside nephrotoxicity with continued drug ad-
ministration. Antimicrob Agents Chemother 14:284—287,
1978
32. GILBERT DN, HOUGHTON DC, BENNETT WN, PLAMP CE,
REGER K, PORTER GA: Reversibility of gentamicin nephro-
toxicity in rats: recovery during continuous drug administra-
tion. Proc Soc Exp Biol Med 160:99-103, 1979
33. LUFT FC, YUM MN, KLEIT SA: The effect of concomitant
mercuric chloride and gentamicin on kidney function and
structure in the rat. J Lab Clin Med 89:622-631, 1977
34. LANE AZ, WRIGHT GE, BLAIRE DC: Ototoxicity and neph-
rotoxicity of amikacin. Am J Med 62:911-918, 1977
Amino glycoside nephrotoxicity 581
35. PLAMP C, BENNETT W, GILBERT D, PORTER G: The effect of
dosage regimen on experimental gentamicin nephrotoxicity:
Dissociation of peak serum levels from renal failure. Clin
Res 26:125A, 1978
36. SCHENTAG JJ, JUSKO Wi, VANCE JW. CUMBO TJ, ABRUTYN
E, DELATTRE M, GERBRACI-1T LM: Gentamicin disposition
and tissue accumulation on multiple dosing. J Pharmacokin
Biopharm 5:559-577, 1977
37. BENNETT WM, HARTNETT MN, GILBERT D, HOUGHTON D,
PORTER GA: Effect of sodium intake on gentamicin nephro-
toxicity in the rat. Proc Soc Exp Biol Med 15 1:736—738, 1976
38. Hsu CH, KURTZ TW, EASTERLING RE, WELLER JM: Poten-
tiation of gentamicin nephrotoxicity by metabolic acidosis.
Proc Soc Exp Biol Med 146:894-897, 1974
39. Hntscti GH: Enhancement of gentamicin nephrotoxicity by
glycerol. Toxicol Appi Pharmacol 29:270-276, 1974
40. BARR GA, MAZZE RI, CousiNs MJ, KosaK JC: An animal
model for combined methoxyflurane and gentamicin nephro-
toxicity. Br JAnesth 45:306—312, 1973
41. SCHENTAG JJ, PLAUT ME, CERRA FB, WELS PB, WALCZAK
P, BUCKLEY RJ: Aminoglycoside nephrotoxicity in critically
ill surgical patients. J Surg Res 26:270—279, 1979
42. SCHENTAG JJ, CUMBO TJ, JUSKO WJ, PLAUT ME: Gen-
tamicin tissue accumulation and nephrotoxic reactions.
JAMA 240:2067-2069, 1978
43. KLASTERSKY J, HANSGENS C, DEBUSSCHER L: Empiric ther-
apy for cancer patients: comparative study of ticarcillin-
tobramycin, ticarcillin-cephalothin, and cephalothin-tobra-
mycin. Antimicrob Agents Chemother 7:640-645, 1975
44. GIAMARELLOU H, PETRIKKOS G, DOUDOULAKI P, DAIKOS
GK: Prospective comparative evaluation of gentamicin
alone and gentamicin plus various cephalosporins with re-
spect to nephrotoxicity in humans, in Current Chemother-
apy, edited by SIEGENTHALER W, LUTHY R, Washington,
D.C., Am. Soc. Microb., 1978, vol. 2, pp. 968-970
45. EORTC International Antimicrobial Therapy Project Group:
Three antibiotic regimens in the treatment of infection in fe-
brile granulocytopenic patients with cancer. J Infect Dis
137: 14—29, 1978
46. WADE JC, SMITH CR, PETTY BG, LIPSKY JJ, CONRAD G,
ELLNER J, LIETMAN PS: Cephalothin plus an amino-
glycoside is more nephrotoxic than methicillin plus an
aminoglycoside. Lancet 2:604-606, 1978
47. HARRISON WO, SILVERBLATT Fi, TURCK M: Gentamicin
nephrotoxicity: failure of three cephalosporins to potentiate
injury in rats. Antimicrob Agents Chemother 8:209—215,
1975
48. LUFT FC, PATEL V, YUM MN, KLEIT SA: Nephrotoxicity
of cephalosporin-gentamicin combination in rats. Anti-
microb Agents Chemother 9:831—839, 1976
49. DELLINGER P, MURPHY T, BAR.ZA M, PINN V. WEINSTEIN
L: Effect of cephalothin on renal cortical concentration of
gentamicin in rats. Antimicrob Agents Chemother 9:587—
588, 1976
50. BARZA M, PINN V, TANGUAY P, MURRAY T: Nephrotoxicity
of newer cephalosporins and aminoglycosides alone and in
combination in a rat model. J Antimicrob Chemother 4
(Suppl A):59—68, 1978
51. Bt.oci-i R, LUFT FC, RANKIN LI, SLOAN RS, YUM MN,
MAXWELL DR: Protection from gentamicin nephrotoxicity
by cephalothin and carbenicillin. Antimicrob Agents Chemo-
ther 15:46—49, 1979
52. ALFTHAN 0, RENKONEN0, SIVONEN A: Concentration of
gentamicin in serum, urine and urogenital tissue in man.
Acta Pathol Microbiol Scand 81 (Suppl):92-94, 1973
53. BENNETT WM, GILBERT DN, HOUGHTON D, PORTER GA:
Gentamicinnephrotoxicity: morphologic and pharmacologic
features. West JMed 126:65—68, 1977
54. EDWARDS CQ, SMITH CR, BAUGHMAN KL, ROGER JF,
LEITMAN PS: Concentrations of gentamicin and amikacin in
human kidneys. Antimicrob Agents Chemother 9:925-927,
1976
55. LUFT FC, KLEIT SA: Renal parenchymal accumulation of
aminoglycoside antibiotics. J Infect Dis 130:656—659, 1974
56. FABRE J, RUDHARDTM, BLANCHARD P, REGAMEY C: Per-
sistence of sisomicin and gentamicin in renal cortex and me-
dulla compared with other organs and serum of rats. Kidney
mt 10:444—449, 1976
57. CHIU PJ, BROWN A, MILLER G, LONG iF: Renal extraction
of gentamicin in anesthetized dogs. Antimicrob Agents
Chemoxher 10:277-282, 1976
58. NEDDEN R, FUCHS T, SCHRODER K, WUNDT W: Die renale
Ausscheidung von Gentamicin beim Mensche. Deut Med
Wochenschr 97: 1496-1503, 1972
59. GY5ELYNCK AM, FORREY A, CUTLER R: Pharmacokinetics
ofgentamicin: distribution and plasma and renal clearance. J
Infect Dis 124 (suppl):S70-576, 1971
60. ROSENKRANZ H, SCHEER M, SCHOLTAN W: Binding of
aminoglycosides to human serum proteins: III. Effect of ex-
perimental conditions. Infection 6:57—64, 1978
61. MYERS DR, DEFEHR J, BENNETT WM, PORTER GA, OLSEN
GD: Gentamicin binding to serum and plasma proteins C/in
Pharmacol Ther 23:356-360, 1978
62. PASTORIZA-MUNOZ E, BOWMAN RL, KALOYANIDES GJ:
Renal tubular transport of gentamicin in the rat. Kidney mt
16:440-450, 1979
63. SENEKJIAN HO, KN!GHTTF, WEINMAN EJ: Micropuncture
study of the renal handling of gentamicin in the rat. Abst Am
Soc Nephrol l2:67A, 1979
64. Hsu CH, KURTZ TW, WELLER JM: In Vitro uptake of gen-
tamicin by rat renal cortical tissue. Antimicrob Agents
Chemother 12:192-194, 1977
65. KLUWE WM, HOOK JB: Analysis of gentamicin uptake by
rat renal cortical slices. Toxicol Appi Pharmacol 45—53 1-
539, 1978
66. COLLIER VU, LIETMAN PS, MITCH WE: Evidence for lumi-
nal uptake of gentamicin in the perfused rat kidney. J Phar-
macal Exp Ther 210:247-251, 1979
67. CHIu PJS, LONG JF: Urinary excretion and tissue accumula-
tionofgentamicin and para-aminohippurate in post ischemic
rat kidneys. Kidney mt 15:618—623, 1979
68, JUST M, ERDMANN G, HABERMANN E: The renal handling of
polybasic drugs: I. Gentamicin and aprotinin in intact ani-
mals. Naunyn-Schmiedebergs Arch Pharmacol 300:57-66,
1977
69. SILVERBLATT FJ, KUEHN C: Autoradiography of gentamicin
by the rat proximal tubular cell. Kidney mt 15:335-345, 1979
70. JUST M, HABERMANN E: The renal handling of polybasic
drugs: 2. In vitro studies with brush border and lysosomal
preparations. Naunyn Schmiedebergs Arch Pharmacol
300:67-76, 1977
71. TULKENS P, AUBERT-TULKENS G, VAN HOFF F, TROUET A:
The lysosomal toxicity of aminoglycosides, in Nephrotoxici-
ty, edited by FILLASTRE JP, New York, Mason Publ. USA
Inc., 1978, pp. 231—251
72. AUBERT-TULKENS G, VAN HOOF F, TULKENS P: Gen-
582 Kaloyanides and Pastoriza-Munoz
tamicin-induced lysosomal phospholipidosis in cultured rat
fibroblasts. Lab Invest 40:481—491, 1979
73. Moiu JP, VIOTTE G, VAN DEWALLE A, VAN HooF F, TUL-
KENS P, FILLASTRE JP: Gentamicin-induced nephrotoxicity:
A cell biology approach. Kidney Int, this issue
74. WHELTON A, CARTER GG, BRYANT HH, CODY TS, CRAIG
TJ, WALKER WG: Intrarenal distribution of amino-
glycosides; nephrotoxicity of aminoglycosides and cephalo-
sporins, in Nephrotoxicity, edited by FILLASTRE JP, New
York, Masson Pubi. USA Inc., 1978, pp. 951-953
75. AUSLANDER DE, FELMEISTER A, SCLARRONE BJ: Drug-bio-
molecule interactions: interaction of gentamicin with lipid
monomolecular films. J Pharmaceut Sci 64:516-519, 1975
76. Cniu PJS, MILLER GH, LONG JF, WALTZ JA: Renal uptake
and nephrotoxicity of gentamicin during urinary alkaliniza-
tion in rats. Clin Exp Pharmacol Physiol 6:317—326, 1979
77. HERS HG, VAN HOFF F: Genetic abnormalities of lyso-
somes, in Lysosomes in Biology and Pathology, edited by
DINGLE J, FELL HB, Amsterdam and London, North-Hol-
land Publishing Co., 1969, vol. 2, pp. 19-40
78. HRUBAN Z, SLESERS A, HOPKINS E: Drug induced and natu-
rally occurring myeloid bodies. Lab Invest 27:62-70, 1972
79. LULLMAN H, LULLMANN-RAUCH R, WASSERMANN 0:
Drug induced phospholipidosis. CRC Critical Rev Toxicol
4: 185—218, 1975
80. LULLMANN H, LULLMANN-RAUCH R, WASSERMANN 0:
Lipidosis induced by amphiphilic cationic drugs. Biochem
Pharmacol 27:1103—1108, 1978
81. MORIN JP, FRESEL J, FILLASTRE JP, VAILLANT R: Amino-
glycoside action on rat kidney lysosomes in vivo and in vi-
tro, in Nephrotoxicity, edited by FILLASTRE JP, New York,
Masson PubI. USA Inc., 1978, pp. 253-263
82. SIMMONS CF JR, BOGUSKY RT, HUMES HD: Inhibitory ef-
fects of gentamicin on renal cortical mitochondrial oxidative
phosphorylation: a primary pathogenetic event in gen-
tamicin nephrotoxicity. Abst Am Soc Nephrol 12:6A, 1979
